<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20190208//EN"
       "JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.4" xml:lang="en">
 <front>
  <journal-meta>
   <journal-id journal-id-type="publisher-id">Clinical Medicine and Pharmacology</journal-id>
   <journal-title-group>
    <journal-title xml:lang="en">Clinical Medicine and Pharmacology</journal-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Клиническая медицина и фармакология</trans-title>
    </trans-title-group>
   </journal-title-group>
   <issn publication-format="print">2409-3750</issn>
  </journal-meta>
  <article-meta>
   <article-id pub-id-type="publisher-id">52619</article-id>
   <article-id pub-id-type="doi">10.12737/2409-3750-2022-8-2-14-20</article-id>
   <article-categories>
    <subj-group subj-group-type="toc-heading" xml:lang="ru">
     <subject>Обзоры</subject>
    </subj-group>
    <subj-group subj-group-type="toc-heading" xml:lang="en">
     <subject>reviews</subject>
    </subj-group>
    <subj-group>
     <subject>Обзоры</subject>
    </subj-group>
   </article-categories>
   <title-group>
    <article-title xml:lang="en">Hyperuricemia and its clinical significance</article-title>
    <trans-title-group xml:lang="ru">
     <trans-title>Гиперурикемия и ее клиническое значение</trans-title>
    </trans-title-group>
   </title-group>
   <contrib-group content-type="authors">
    <contrib contrib-type="author">
     <name-alternatives>
      <name xml:lang="ru">
       <surname>Карабаева</surname>
       <given-names>Ф. У.</given-names>
      </name>
      <name xml:lang="en">
       <surname>Karabaeva</surname>
       <given-names>F. U.</given-names>
      </name>
     </name-alternatives>
     <xref ref-type="aff" rid="aff-1"/>
    </contrib>
   </contrib-group>
   <aff-alternatives id="aff-1">
    <aff>
     <institution xml:lang="ru">Андижанский государственный медицинский институт</institution>
     <city>Андижан</city>
     <country>Узбекистан</country>
    </aff>
    <aff>
     <institution xml:lang="en">Андижанский государственный медицинский институт</institution>
     <city>Андижан</city>
     <country>Uzbekistan</country>
    </aff>
   </aff-alternatives>
   <pub-date publication-format="print" date-type="pub" iso-8601-date="2022-09-07T13:22:19+03:00">
    <day>07</day>
    <month>09</month>
    <year>2022</year>
   </pub-date>
   <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2022-09-07T13:22:19+03:00">
    <day>07</day>
    <month>09</month>
    <year>2022</year>
   </pub-date>
   <volume>8</volume>
   <issue>2</issue>
   <fpage>14</fpage>
   <lpage>20</lpage>
   <history>
    <date date-type="received" iso-8601-date="2022-09-02T00:00:00+03:00">
     <day>02</day>
     <month>09</month>
     <year>2022</year>
    </date>
   </history>
   <self-uri xlink:href="https://zh-szf.ru/en/nauka/article/52619/view">https://zh-szf.ru/en/nauka/article/52619/view</self-uri>
   <abstract xml:lang="ru">
    <p>Вопросы патогенеза гиперурикемии в настоящее время остаются актуальными в связи с неуклонным ростом частоты гиперурикемии и подагры при полиморбидных  патологиях. В настоящее время накоплено достаточное количество научных работ об ассоциации гиперурикемии с сердечно-сосудистыми заболеваниями и их последствиями (инсульт и инфаркт миокарда), метаболическим синдромом, артериальной гипертензией, инсулинорезистентностью, сахарным диабетом 2-го типа, хронической болезнью почек, нарушениями липидного обмена, фибрилляцией предсердий, с риском смертности.</p>
   </abstract>
   <trans-abstract xml:lang="en">
    <p>The issues of the pathogenesis of hyperuricemia currently remain relevant due to the steady increase in the frequency of hyperuricemia and gout in polymorbid pathologies. Currently, a sufficient number of scientific papers have been accumulated on the association of hyperuricemia with cardiovascular diseases and their consequences (stroke and myocardial infarction), metabolic syndrome, arterial hypertension, insulin resistance, type 2 diabetes mellitus, chronic kidney disease, lipid metabolism disorders, atrial fibrillation, with the risk of mortality.</p>
   </trans-abstract>
   <kwd-group xml:lang="ru">
    <kwd>пуриновый обмен</kwd>
    <kwd>гиперурикемия</kwd>
    <kwd>подагра</kwd>
    <kwd>коморбидные заболевания.</kwd>
   </kwd-group>
   <kwd-group xml:lang="en">
    <kwd>purine metabolism</kwd>
    <kwd>hyperuricemia</kwd>
    <kwd>gout</kwd>
    <kwd>comorbid diseases</kwd>
   </kwd-group>
  </article-meta>
 </front>
 <body>
  <p></p>
 </body>
 <back>
  <ref-list>
   <ref id="B1">
    <label>1.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Елисеева М.Е., Елисеев М.С. Значение гиперурикемии в развитии заболеваний человека и методы ее коррекции Кардиология Терапия № 2 (157), 2019 стр.47-56</mixed-citation>
     <mixed-citation xml:lang="en">Eliseeva M.E., Eliseev M.S. Znachenie giperurikemii v razvitii zabolevaniy cheloveka i metody ee korrekcii Kardiologiya Terapiya № 2 (157), 2019 str.47-56</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B2">
    <label>2.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Park J.J., Roudier M.P., Soman D., Mokadam N.A., Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014; 4(7): e005308. DOI: 10.1136/</mixed-citation>
     <mixed-citation xml:lang="en">Park J.J., Roudier M.P., Soman D., Mokadam N.A., Simkin P.A. Prevalence of birefringent crystals in cardiac and prostatic tissues, an observational study. BMJ Open. 2014; 4(7): e005308. DOI: 10.1136/</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B3">
    <label>3.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Dalbeth N., House M.E., Aati O., Tan P., Franklin C., Horne A. et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann. Rheum. Dis. 2015; 74(5): 908-11.DOI: 10.1136/annrheumdis-2014-206397</mixed-citation>
     <mixed-citation xml:lang="en">Dalbeth N., House M.E., Aati O., Tan P., Franklin C., Horne A. et al. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann. Rheum. Dis. 2015; 74(5): 908-11.DOI: 10.1136/annrheumdis-2014-206397</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B4">
    <label>4.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Nakagawa Т., Mazzali M., Kang D-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.</mixed-citation>
     <mixed-citation xml:lang="en">Nakagawa T., Mazzali M., Kang D-H. et al. Hyperuricemia causes glomerular hypertrophy in the rat. Am J Nephrol 2003;23:2-7.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B5">
    <label>5.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)</mixed-citation>
     <mixed-citation xml:lang="en">Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B6">
    <label>6.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Денисов ИС, Елисеев МС, Барскова ВГ. Исходы подагры. Обзор литературы. Часть II. Коморбидные заболевания, риск развития сердечно-сосудистых катастроф и смерти при подагре. Научно-практическая ревматология. 2013;51(6):703-10.</mixed-citation>
     <mixed-citation xml:lang="en">Denisov IS, Eliseev MS, Barskova VG. Ishody podagry. Obzor literatury. Chast' II. Komorbidnye zabolevaniya, risk razvitiya serdechno-sosudistyh katastrof i smerti pri podagre. Nauchno-prakticheskaya revmatologiya. 2013;51(6):703-10.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B7">
    <label>7.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466</mixed-citation>
     <mixed-citation xml:lang="en">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B8">
    <label>8.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Елисеев М.С., Новикова А.М. Коморбидность при подагре и гиперурикемии: распространенность, причины, перспективы уратснижающей терапии. Терапевтический архив. 2019; 91 (5): 120-128. DOI: 10.26442/00403660.2019.05.000232</mixed-citation>
     <mixed-citation xml:lang="en">Eliseev M.S., Novikova A.M. Komorbidnost' pri podagre i giperurikemii: rasprostranennost', prichiny, perspektivy uratsnizhayuschey terapii. Terapevticheskiy arhiv. 2019; 91 (5): 120-128. DOI: 10.26442/00403660.2019.05.000232</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B9">
    <label>9.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Узбекова Н.Р. Нейрогуморальные механизмы патогенеза метаболического синдрома. Диссер.докт.мед.наук, Ташкент, 2017</mixed-citation>
     <mixed-citation xml:lang="en">Uzbekova N.R. Neyrogumoral'nye mehanizmy patogeneza metabolicheskogo sindroma. Disser.dokt.med.nauk, Tashkent, 2017</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B10">
    <label>10.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Майко О.Ю., Иванова К.В. Некоторые Аспекты Рациональной Терапии Артериальной Гипертонии У Больных Подагрой И Бессимптомной Гиперурикемией, Клиническая Геронтология, 5-6, 2015 Стр60-67,</mixed-citation>
     <mixed-citation xml:lang="en">Mayko O.Yu., Ivanova K.V. Nekotorye Aspekty Racional'noy Terapii Arterial'noy Gipertonii U Bol'nyh Podagroy I Bessimptomnoy Giperurikemiey, Klinicheskaya Gerontologiya, 5-6, 2015 Str60-67,</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B11">
    <label>11.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431-40.</mixed-citation>
     <mixed-citation xml:lang="en">Johnson R.J., Rodriguez-Iturbe B., Kang D.H. et al. A unifying pathway for essential hypertension. Am J Hypertens 2005;18:431-40.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B12">
    <label>12.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10</mixed-citation>
     <mixed-citation xml:lang="en">Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B13">
    <label>13.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Барскова В.Г. и др. Диагностика подагры (лекция) // Научно-практическая ревматология. 2012. № 4. С. 62-66</mixed-citation>
     <mixed-citation xml:lang="en">Barskova V.G. i dr. Diagnostika podagry (lekciya) // Nauchno-prakticheskaya revmatologiya. 2012. № 4. S. 62-66</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B14">
    <label>14.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Xue Li. Phenome-wide association study (PheWAS) on the genetic determinants of serum urate leveland disease outcomes in UK Biobank. Doctor of Philosophy - The University of Edinburgh - 2018.</mixed-citation>
     <mixed-citation xml:lang="en">Xue Li. Phenome-wide association study (PheWAS) on the genetic determinants of serum urate leveland disease outcomes in UK Biobank. Doctor of Philosophy - The University of Edinburgh - 2018.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B15">
    <label>15.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Biscaglia S., Ceconi C., Malagù M., Pavasini R., Ferrari R. Uric acid and coronary artery disease: An elusive link deserving further attention. Int. J. Cardiol. 2016; 213: 28-32.</mixed-citation>
     <mixed-citation xml:lang="en">Biscaglia S., Ceconi C., Malagù M., Pavasini R., Ferrari R. Uric acid and coronary artery disease: An elusive link deserving further attention. Int. J. Cardiol. 2016; 213: 28-32.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B16">
    <label>16.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Кобалава Ж.Д., Троицкая Е.А. Бессимптомная гиперурикемия и риск развития сердечно-сосудистых и почечных заболеваний. Кардиология. 2020;60(10):113-121</mixed-citation>
     <mixed-citation xml:lang="en">Kobalava Zh.D., Troickaya E.A. Bessimptomnaya giperurikemiya i risk razvitiya serdechno-sosudistyh i pochechnyh zabolevaniy. Kardiologiya. 2020;60(10):113-121</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B17">
    <label>17.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Current opinion in rheumatology. 2014;26(2):186-91</mixed-citation>
     <mixed-citation xml:lang="en">Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Current opinion in rheumatology. 2014;26(2):186-91</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B18">
    <label>18.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? European review for medical and pharmacological sciences. 2014;18(9):1295-306.</mixed-citation>
     <mixed-citation xml:lang="en">Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? European review for medical and pharmacological sciences. 2014;18(9):1295-306.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B19">
    <label>19.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Richette P, Doherty M, Pascual E, et al. Ann Rheum Dissertation 2020;79:33.</mixed-citation>
     <mixed-citation xml:lang="en">Richette P, Doherty M, Pascual E, et al. Ann Rheum Dissertation 2020;79:33.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B20">
    <label>20.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">«Обновленные в 2018 г. рекомендации Европейской противоревматической лиги по диагностике подагры, основанные на фактических данных» (2020г.)</mixed-citation>
     <mixed-citation xml:lang="en">«Obnovlennye v 2018 g. rekomendacii Evropeyskoy protivorevmaticheskoy ligi po diagnostike podagry, osnovannye na fakticheskih dannyh» (2020g.)</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B21">
    <label>21.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Рекомендации Французского общества ревматологов 2020 г.</mixed-citation>
     <mixed-citation xml:lang="en">Rekomendacii Francuzskogo obschestva revmatologov 2020 g.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B22">
    <label>22.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">В.В. Цурко, И.В. Егоров, М.В. Елисеева//Подагра у пожилых пациентов, связь с коморбидностью / Практикующий врач сегодня. 2013. №1. С. 2-9.</mixed-citation>
     <mixed-citation xml:lang="en">V.V. Curko, I.V. Egorov, M.V. Eliseeva//Podagra u pozhilyh pacientov, svyaz' s komorbidnost'yu / Praktikuyuschiy vrach segodnya. 2013. №1. S. 2-9.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B23">
    <label>23.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466</mixed-citation>
     <mixed-citation xml:lang="en">Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57(1):109-15. doi: 10.1002/art.22466</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B24">
    <label>24.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Елисеев М.С., Барскова В.Г., Денисов И.С. Динамика клинических проявлений подагры у мужчин (данные 7-летнего ретроспективного наблюдения). Терапевтический архив. - 2015.Т. 87. - № 5. - С. 10-5.</mixed-citation>
     <mixed-citation xml:lang="en">Eliseev M.S., Barskova V.G., Denisov I.S. Dinamika klinicheskih proyavleniy podagry u muzhchin (dannye 7-letnego retrospektivnogo nablyudeniya). Terapevticheskiy arhiv. - 2015.T. 87. - № 5. - S. 10-5.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B25">
    <label>25.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Бекматова Ш.К. Структура Метаболического Синдрома И Его Клиническое Значение В Различные Периоды Жизни, диссер. PhD, Ургенч,2021стр.5</mixed-citation>
     <mixed-citation xml:lang="en">Bekmatova Sh.K. Struktura Metabolicheskogo Sindroma I Ego Klinicheskoe Znachenie V Razlichnye Periody Zhizni, disser. PhD, Urgench,2021str.5</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B26">
    <label>26.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Cicero A.F., Rosticci M., Fogacci F., Grandi E., D'Addato S., Borghi C.; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur. J. Intern. Med. 2017; 37: 38-42. DOI:10.1016/j.ejim.2016.07.026.</mixed-citation>
     <mixed-citation xml:lang="en">Cicero A.F., Rosticci M., Fogacci F., Grandi E., D'Addato S., Borghi C.; Brisighella Heart Study Group. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. Eur. J. Intern. Med. 2017; 37: 38-42. DOI:10.1016/j.ejim.2016.07.026.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B27">
    <label>27.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ramirez A.J., Christen A.I., Sanchez R.A. Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances. Curr. Hypertens. Rev. 2018; 14(2): 154-60. DOI:10.2174/1573402114666180413143312</mixed-citation>
     <mixed-citation xml:lang="en">Ramirez A.J., Christen A.I., Sanchez R.A. Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances. Curr. Hypertens. Rev. 2018; 14(2): 154-60. DOI:10.2174/1573402114666180413143312</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B28">
    <label>28.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Руда М.М., Карпов Ю.А.. Гиперурикемия и сердечно-сосудистый риск: современный взгляд на проблему. АтмосферA. Новости кардиологии 1*2020стр3-15</mixed-citation>
     <mixed-citation xml:lang="en">Ruda M.M., Karpov Yu.A.. Giperurikemiya i serdechno-sosudistyy risk: sovremennyy vzglyad na problemu. AtmosferA. Novosti kardiologii 1*2020str3-15</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B29">
    <label>29.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Тоиров Х.К., Кардиоваскулярные нарушения при подагре. Дисст. кмн.2013.Душанбе</mixed-citation>
     <mixed-citation xml:lang="en">Toirov H.K., Kardiovaskulyarnye narusheniya pri podagre. Disst. kmn.2013.Dushanbe</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B30">
    <label>30.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Тополянская С.В., Вакуленко О.Н., Семашкова А.Е., Купина Л.М., Стрижова Н.В. Гиперурикемия и сердечно-сосудистые заболевания в старческом возрасте. Клин. Мед. 2017; 95 (5): 457-464.DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-457-464</mixed-citation>
     <mixed-citation xml:lang="en">Topolyanskaya S.V., Vakulenko O.N., Semashkova A.E., Kupina L.M., Strizhova N.V. Giperurikemiya i serdechno-sosudistye zabolevaniya v starcheskom vozraste. Klin. Med. 2017; 95 (5): 457-464.DOI http://dx.doi.org/10.18821/0023-2149-2017-95-5-457-464</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B31">
    <label>31.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Campo C., Ruilope L.M., Segura J. et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood press. 2003; 12: 277-283.</mixed-citation>
     <mixed-citation xml:lang="en">Campo C., Ruilope L.M., Segura J. et al. Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. Blood press. 2003; 12: 277-283.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B32">
    <label>32.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Puddu P., Puddu G.M., Cravero E., Vizioli L., Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications.J. Cardiol. 2012; 59: 235-42.</mixed-citation>
     <mixed-citation xml:lang="en">Puddu P., Puddu G.M., Cravero E., Vizioli L., Muscari A. The relationships among hyperuricemia, endothelial dysfunction, and cardiovascular diseases: Molecular mechanisms and clinical implications.J. Cardiol. 2012; 59: 235-42.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B33">
    <label>33.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-72</mixed-citation>
     <mixed-citation xml:lang="en">Puig J.G., Ruilope L.M. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-72</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B34">
    <label>34.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Qin T., Zhou X., Wang J., Wu X., Li Y., Wang L. et al. Hyperuricemia andthe Prognosis of Hypertensive Patients: A Systematic Reviewand MetaAnalysis. J. Clin. Hypertens. (Greenwich). 2016; 18(12): 1268-78. DOI:10.1111/jch.12855</mixed-citation>
     <mixed-citation xml:lang="en">Qin T., Zhou X., Wang J., Wu X., Li Y., Wang L. et al. Hyperuricemia andthe Prognosis of Hypertensive Patients: A Systematic Reviewand MetaAnalysis. J. Clin. Hypertens. (Greenwich). 2016; 18(12): 1268-78. DOI:10.1111/jch.12855</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B35">
    <label>35.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T, Hisatome I. Hyperuricemia is an independent competing risk factor for atrial fibrillation. International Journal of Cardiology 2017 Mar;231:137-42</mixed-citation>
     <mixed-citation xml:lang="en">Kuwabara M, Niwa K, Nishihara S, Nishi Y, Takahashi O, Kario K, Yamamoto K, Yamashita T, Hisatome I. Hyperuricemia is an independent competing risk factor for atrial fibrillation. International Journal of Cardiology 2017 Mar;231:137-42</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B36">
    <label>36.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J. Rheumatol. 2000; 27(6): 1501-5.;</mixed-citation>
     <mixed-citation xml:lang="en">Lin K.C., Lin H.Y., Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J. Rheumatol. 2000; 27(6): 1501-5.;</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B37">
    <label>37.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)</mixed-citation>
     <mixed-citation xml:lang="en">Lehto S., Niskanen L., Ronnemaa T. et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-independent diabetes mellitus. Stroke. 1998; 29: 635-9)</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B38">
    <label>38.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Недогода С.В., Саласюк А.С., Барыкина И.Н., Ледяева А.А., Цома В.В., Чумачек Е.В., Хрипаева В.Ю. Возможности Коррекции Гиперурикемии При Метаболическом Синдроме.Медицинский совет №2,2014 стр 18-24</mixed-citation>
     <mixed-citation xml:lang="en">Nedogoda S.V., Salasyuk A.S., Barykina I.N., Ledyaeva A.A., Coma V.V., Chumachek E.V., Hripaeva V.Yu. Vozmozhnosti Korrekcii Giperurikemii Pri Metabolicheskom Sindrome.Medicinskiy sovet №2,2014 str 18-24</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B39">
    <label>39.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port, 2011, 2: 565-574.</mixed-citation>
     <mixed-citation xml:lang="en">Abreu E, Fonseca MJ, Santos AC. Association between hyperuricemia and insulin resistance. Acta Med Port, 2011, 2: 565-574.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B40">
    <label>40.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Ильина А.Е., Барскова В.Г., Насонов Е.Л. Бессимптомная гиперурикемия - польза или вред? РМЖ. - 2008. - № 24. - С. 1619. / Il'ina AE, Barskova VG, Nasonov EL. Bessimptomnaya giperurikemiya - pol'za ili vred? RMZH. 2008; 24: 1619. [in Russian].</mixed-citation>
     <mixed-citation xml:lang="en">Il'ina A.E., Barskova V.G., Nasonov E.L. Bessimptomnaya giperurikemiya - pol'za ili vred? RMZh. - 2008. - № 24. - S. 1619. / Il'ina AE, Barskova VG, Nasonov EL. Bessimptomnaya giperurikemiya - pol'za ili vred? RMZH. 2008; 24: 1619. [in Russian].</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B41">
    <label>41.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Орлова Е.В.Гиперурикемия в терапевтической практике - лечить или наблюдать/ Трудный пациент №10, ТОМ 16, 2018 стр.17 DOI: 10.24411/2074-1995-2018-10015)</mixed-citation>
     <mixed-citation xml:lang="en">Orlova E.V.Giperurikemiya v terapevticheskoy praktike - lechit' ili nablyudat'/ Trudnyy pacient №10, TOM 16, 2018 str.17 DOI: 10.24411/2074-1995-2018-10015)</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B42">
    <label>42.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10</mixed-citation>
     <mixed-citation xml:lang="en">Fang J., Alderman M. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA. 2000; 238:2404-10</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B43">
    <label>43.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Барскова ВГ, Ильиных ЕВ, Елисеев МС и др. Кардиоваскулярный риск у больных подагрой. Ожирение и метаболизм. 2006;(3):40-44.</mixed-citation>
     <mixed-citation xml:lang="en">Barskova VG, Il'inyh EV, Eliseev MS i dr. Kardiovaskulyarnyy risk u bol'nyh podagroy. Ozhirenie i metabolizm. 2006;(3):40-44.</mixed-citation>
    </citation-alternatives>
   </ref>
   <ref id="B44">
    <label>44.</label>
    <citation-alternatives>
     <mixed-citation xml:lang="ru">Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45: 991- 996</mixed-citation>
     <mixed-citation xml:lang="en">Viazzi F., Parodi D., Leoncini G. et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45: 991- 996</mixed-citation>
    </citation-alternatives>
   </ref>
  </ref-list>
 </back>
</article>
